SCHEMBL13833256

SCHEMBL13833256

Cc1cc(NC(=O)OC(C)(C)C)cc(B2OC(C)(C)C(C)(C)O2)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 2/20 0.43
PRMT5 O14744 1/20 0.42
WDR77 Q9BQA1 1/20 0.42
CA1 P00915 2/20 0.39
CA9 Q16790 2/20 0.39
CA12 O43570 1/20 0.39
NR1I2 O75469 1/20 0.38
HIF1A Q16665 2/20 0.37
LCK P06239 2/20 0.35
DGAT1 O75907 1/20 0.35
PSMB8 P28062 1/20 0.34
NAMPT P43490 1/20 0.34
USP30 Q70CQ3 2/20 0.34
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34
CA2 P00918 1/20 0.34
BACE1 P56817 1/20 0.34
BACE2 Q9Y5Z0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21318698 0.92 AAK1 (0.46) AAK1PRMT5WDR77CA1CA9
SCHEMBL19826506 0.86 AAK1 (0.42) AAK1PRMT5WDR77CA1CA9
SCHEMBL18668117 0.84 KDM4E (0.42) AAK1PRMT5WDR77CA1CA9
SCHEMBL29953321 0.83 SIRT2 (0.44) AAK1PRMT5WDR77
SCHEMBL13738256 0.82 HIF1A (0.39) CA1CA9CA12NR1I2HIF1A
SCHEMBL31486104 0.82 AAK1 (0.39) AAK1PRMT5WDR77CA1CA9
SCHEMBL1300326 0.82 PRMT5 (0.47) AAK1PRMT5WDR77CA1CA9
SCHEMBL29895473 0.82 PRMT5 (0.47) AAK1PRMT5WDR77CA1CA9
SCHEMBL1255934 0.81 AAK1 (0.54) AAK1PRMT5WDR77CA1CA9
SCHEMBL1502647 0.81 PRMT5 (0.44) AAK1PRMT5WDR77CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187486-B2 Bicyclic pyridazine compounds as Pim inhibitors AMGEN INC. (US) 2015-11-17 US disclosed
US-9187486-B2 Bicyclic pyridazine compounds as Pim inhibitors AMGEN INC. (US) 2015-11-17 US disclosed
US-20140221344-A1 Bicyclic Pyridazine Compounds as PIM Inhibitors AMGEN INC. 2014-08-07 US disclosed
US-20140221344-A1 Bicyclic Pyridazine Compounds as PIM Inhibitors AMGEN INC. 2014-08-07 US disclosed
WO-2012148775-A1 BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221344-A1 Bicyclic Pyridazine Compounds as PIM Inhibitors PIM1, PIM2, PIM3 AAK1 235/4885PRMT5 19/4885WDR77 2525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.